Evidence map›Paper›PMID 42750682›Full record

ReviewFrontiers in oncology2026

Human papilloma virus as causal in breast cancer.

James S Lawson, Wendy K Glenn

Abstract readReview
In one paragraph

Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

James S LawsonSchool of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, NSW, Australia.
Wendy K GlennSchool of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, NSW, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this review is to consider the role of high-risk human papillomaviruses (HPVs) in breast cancer. HPVs have established causal roles in cancers of the cervix, anus, penis, vagina, vulva, and oropharyngeal cancers. High-risk HPVs have been consistently detected in breast cancers in 23 countries. HPVs have been identified in 32.7% of breast cancers as compared to 7.6% of benign and normal breast controls. HPV-positive benign breast lesions can progress to HPV-positive malignancies, suggesting an early role of HPVs in carcinogenesis. HPV biological activity has been demonstrated by the detection of HPV transcripts, HPV oncogenic protein expression (HPV E6/E7), and HPV-induced koilocytes in breast cancer tissues. HPVs sourced from normal breast tissues and human milk can immortalise normal cultured breast epithelial cells. There is a plausible mechanism for the transfer of HPV material from the genital tract and cervix to the breast via blood and circulating exosomes. HPV-associated breast cancer is probably via a "hit and run" causal mechanism. The influence of HPV vaccination in reducing the incidence of breast cancer by 18% to 19% offers supportive evidence of causation. Other oncogenic viruses, including mouse mammary tumour virus, Epstein-Barr virus, and bovine leukaemia virus, may contribute to breast carcinogenesis independently or synergistically with high-risk HPVs. The evidence meets the extended Bradford Hill causal criteria. High-risk HPVs probably have a causal role in a subset of breast cancers.

Indexed as

breast cancercausalevidencehuman papillomavirusviruses

Identifiers

PMID42750682
PMCPMC13577847

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.